FLASCO

FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors

  • FLASCO
  • November 17, 2017

FDA approved emicizumab-kxwh (HEMLIBRA, Genentech, Inc.) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. More Information.  November 16, 2017​

Other Hematology/Oncology (Cancer) Approvals & Safety Notifications

Who’s Online

There are no users currently online